A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Today's AI agents are a primitive approximation of what agents are meant to be. True agentic AI requires serious advances in reinforcement learning and complex memory.

How do caterpillars keep memories after dissolving into soup? How do we transform without fragmenting? A new AI architecture ...